medicin aid treatment drug fight anemia patient azt genet engin drug decreas blood transfus requir aid patient take wide use aid drug azt accord small studi publish today new england journal medicin drug recombin human erythropoietin stimul product oxygen carri red blood cell alreadi avail aid patient u food drug administr expand access program may approv prescript sale later year azt therapi increasingli recommend aid patient pre aid condit mean control human immunodefici viru caus diseas mani patient need receiv blood transfus modifi use drug develop low red blood cell count anemia drug decreas frequenc azt relat anemia stimul bone marrow produc red blood cell would eas demand blood transfus allow patient benefit azt erythropoietin clone hormon name normal present bodi research found aid patient small amount erythropoietin blood like respond thrice weekli inject drug patient higher concentr three quarter aid patient low erythropoietin level accord dr steven mile senior aid investig ucla medic center one author studi drug work mile said effect adjunct specif therapi aid patient may still viru complic relat one less problem deal mile said ongo research suggest advanc aid care increas potenti effect erythropoietin patient typic treat lower dose azt zidovudin use studi result anemia less like occur easier revers addit aid patient switch drug caus anemia experiment drug ddi erythropoietin market brand name epogen amgen inc thousand oak success use treat anemia associ chronic kidney diseas drug also use athlet enhanc perform practic research believ danger even fatal excess number red blood cell caus blood otherwis healthi peopl thicken creat risk stroke heart attack studi fund ortho pharmaceut corp raritan n j approv u food drug administr develop erythropoietin aid relat therapi ortho yet said much erythropoietin cost ortho charg vial medic similar amgen year suppli aid patient cost 4 000 mile said reason well understood aid patient take azt wide vari concentr erythropoietin bloodstream three month studi 29 patient receiv erythropoietin inject 34 receiv placebo inject begin studi aid patient low erythropoietin level requir averag 1 5 unit blood month end studi receiv erythropoietin requir averag 0 84 unit blood month receiv placebo requir averag 2 74 unit blood month comparison begin studi aid patient high erythropoietin level requir averag 3 2 unit blood month end studi receiv erythropoietin requir averag 3 5 unit blood month receiv placebo requir 2 78 unit blood month differ statist signific